A Comprehensive Clinical Monograph on the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)

Executive Summary

The 23-valent pneumococcal polysaccharide vaccine (PPSV23), marketed principally as Pneumovax 23, represents a cornerstone of adult immunization strategies against disease caused by the bacterium Streptococcus pneumoniae. For decades, it has been the primary tool for preventing pneumococcal infections in older adults and those with high-risk medical conditions. This monograph provides a comprehensive clinical review of PPSV23, synthesizing evidence on its pharmacology, immunology, clinical effectiveness, and its evolving role within contemporary vaccination guidelines.

The vaccine's mechanism of action is predicated on a T-cell independent immune response, which effectively stimulates the production of opsonizing antibodies against the 23 capsular polysaccharide serotypes contained within its formulation. This mechanism underpins both its primary strength and its key limitations. Clinical evidence robustly supports the effectiveness of PPSV23 in preventing invasive pneumococcal disease (IPD), including life-threatening conditions such as bacteremia and meningitis. Meta-analyses confirm a pooled effectiveness of approximately 45% against vaccine-type IPD in adults. However, its efficacy in preventing non-bacteremic pneumococcal pneumonia (NBPP) is inconsistent and, according to recent meta-analyses, not statistically significant. This crucial distinction reframes the vaccine's primary value proposition as a targeted intervention against severe, invasive disease rather than a general "pneumonia vaccine."

The T-cell independent nature of the immune response also results in the generation of limited immunologic memory and a poor anamnestic response, necessitating revaccination for certain high-risk groups. Furthermore, it is poorly immunogenic in children under two years of age, a population for whom pneumococcal conjugate vaccines (PCVs) are the standard of care. The advent of highly immunogenic PCVs for adults has fundamentally altered the pneumococcal vaccination landscape. Current recommendations from the Advisory Committee on Immunization Practices (ACIP) position PPSV23 not as a standalone primary vaccine for most adults, but as a critical component of a sequential vaccination strategy, typically administered following a dose of a PCV (specifically PCV15). This strategy is designed to leverage the robust, T-cell dependent memory response of the PCV while capitalizing on the broader serotype coverage of PPSV23. While its role has evolved, PPSV23 remains an indispensable tool for maximizing protection against the diverse serotypes of S. pneumoniae in vulnerable adult populations.

Introduction and Historical Context

The Global Burden of Streptococcus pneumoniae Disease

Streptococcus pneumoniae is a Gram-positive bacterium that remains a leading cause of morbidity and mortality worldwide.[1] It is the most common etiologic agent of community-acquired pneumonia (CAP), accounting for an estimated 10% to 25% of all cases.[2] The clinical spectrum of pneumococcal disease is broad, ranging from relatively mild, non-invasive infections such as otitis media and sinusitis to severe, life-threatening invasive pneumococcal disease (IPD), which occurs when the bacterium invades normally sterile sites.[1] The most severe manifestations of IPD are bacteremia, sepsis, and meningitis.[1]

The epidemiology of pneumococcal disease follows a distinct bimodal pattern, with the highest incidence rates observed at the extremes of age: in young children under two years and in older adults, particularly those aged 65 years and older.[1] In the United States alone, pneumococcal disease is responsible for thousands of deaths among adults each year, with an estimated 18,000 fatalities occurring in adults aged 65 and older.[4] The mortality associated with IPD is substantial; pneumococcal bacteremia carries a case-fatality rate of approximately 1 in 5 (20%), while pneumococcal meningitis is fatal in up to 3 out of 10 cases.[4] Even among survivors, severe pneumococcal disease can lead to long-term sequelae, including hearing loss and brain damage.[3]

The Evolution of Pneumococcal Vaccines

The development of vaccines to combat pneumococcal disease has a long and complex history, one that is deeply intertwined with the advent of antimicrobial therapy. The first polysaccharide-based pneumococcal vaccine, a tetravalent formulation, was developed in 1945.[5] However, its deployment coincided with the discovery and widespread introduction of penicillin, a highly effective treatment for pneumococcal infections at the time. The perceived power of antibiotics to cure the disease overshadowed the preventative potential of the vaccine, leading to its limited use and a subsequent focus on treatment over prevention.[5]

This paradigm began to shift in the latter half of the 20th century as S. pneumoniae developed increasing resistance to penicillin and other classes of antibiotics.[7] The growing threat of difficult-to-treat infections created a renewed public health imperative for effective prevention. This led to a resurgence of interest in vaccine development, championed by researchers like Robert Austrian in the 1970s, which resulted in the licensure of a 14-valent pneumococcal polysaccharide vaccine.[5]

This evolution culminated in 1983 with the approval of the 23-valent pneumococcal polysaccharide vaccine (PPSV23).[1] This formulation was a significant advancement, designed to provide broader protection by including purified capsular polysaccharide antigens from 23 of the most common serotypes causing disease in the United States and worldwide at the time of its development. The 23 serotypes included are: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.[5] Together, these serotypes were estimated to cover approximately 90% of the strains responsible for invasive bloodstream infections, making PPSV23 a critical tool in the public health armamentarium against pneumococcal disease.[5]

Pharmacology and Comparative Immunology

Composition and Formulation of PPSV23

PPSV23 (Pneumovax 23) is a sterile, liquid vaccine prepared from purified capsular polysaccharide antigens of S. pneumoniae.[5] The vaccine is formulated to contain 25 µg of each of the 23 distinct polysaccharide antigens in a single 0.5 mL dose.[10] The final product is a clear solution that may contain 0.25% phenol as a preservative.[10] It is supplied for clinical use in both single-dose vials and prefilled syringes.[8]

Mechanism of Action: The T-Cell Independent Immune Response

The immunological mechanism of PPSV23 is fundamentally different from that of protein-based or conjugate vaccines. As a pure polysaccharide vaccine, it induces a T-cell independent (TI) immune response.[7] The long, repetitive polysaccharide antigens are capable of cross-linking multiple B-cell receptors (BCRs) on the surface of specific B-lymphocytes simultaneously. This extensive cross-linking provides a strong enough signal to activate the B-cell directly, causing it to proliferate and differentiate into antibody-producing plasma cells without the requirement for "help" from T-helper cells.[13]

The resulting antibodies are type-specific and play a crucial role in host defense by acting as opsonins. They bind to the bacterial capsule, marking the encapsulated bacteria for enhanced recognition and engulfment by phagocytic immune cells (opsonization), leading to more efficient phagocytosis and killing of the pathogen.[5] A protective antibody response typically develops within two to three weeks of vaccination.[9]

However, the TI nature of this response carries significant immunological limitations. The response primarily generates low-affinity IgM antibodies and does not effectively induce antibody class-switching to long-lived IgG isotypes.[14] Critically, it fails to establish a robust population of memory B-cells or long-lived plasma cells.[13] This results in an immune response that is relatively short-lived and does not produce a strong anamnestic (booster) effect upon subsequent exposure to the antigen or revaccination.[18]

Comparative Immunogenicity: PPSV23 vs. Pneumococcal Conjugate Vaccines (PCVs)

The limitations of polysaccharide vaccines led to the development of pneumococcal conjugate vaccines (PCVs), such as PCV13, PCV15, PCV20, and PCV21.[4] The defining feature of PCVs is the covalent linkage (conjugation) of the polysaccharide antigen to a highly immunogenic carrier protein, such as a non-toxic variant of diphtheria toxin known as CRM197.[9]

This molecular engineering fundamentally transforms the nature of the immune response from T-cell independent to T-cell dependent.[11] When a B-cell recognizes and internalizes the conjugate vaccine via its polysaccharide-specific BCR, it processes not only the polysaccharide but also the attached carrier protein. The B-cell then presents peptides derived from the carrier protein on its surface via Major Histocompatibility Complex (MHC) class II molecules. These peptide-MHC complexes are recognized by carrier protein-specific T-helper cells, which then provide co-stimulatory signals to the B-cell. This T-cell help is essential for driving a more mature and robust immune response, characterized by:

• [Antibody Class-Switching:] Production of high-affinity IgG antibodies, which are more effective and longer-lasting than IgM.[14]
• [Affinity Maturation:] A process within germinal centers that refines the antibodies to bind more tightly to the target antigen.[22]
• [Generation of Immunologic Memory:] The establishment of long-lived memory B-cells and plasma cells that can mount a rapid and powerful anamnestic response upon future encounters with the pathogen.[21]

Direct comparative studies in adults have consistently demonstrated the immunological superiority of PCVs. Clinical trials have shown that PCVs induce a significantly greater functional antibody response, as measured by opsonophagocytic killing assays (OPA), compared to PPSV23 for the serotypes common to both vaccines, and this enhanced response persists for at least two years.[11]

The Phenomenon of Immune Blunting in Sequential Vaccination

The distinct immunological pathways engaged by PPSV23 and PCVs have profound implications for sequential vaccination strategies. A critical phenomenon known as "immune blunting" or "hyporesponsiveness" has been observed in clinical studies.[18] When PPSV23 is administered first, it can lead to a diminished or "blunted" immune response to a subsequent dose of a PCV administered later.[18] The precise mechanism is not fully elucidated but is thought to involve the depletion or anergizing of the specific B-cell pool by the initial T-cell independent stimulation.

Conversely, administering a PCV first appears to "prime" the immune system. The T-cell dependent response generates a robust pool of memory B-cells. When these memory cells are later stimulated by a dose of PPSV23 containing the same serotypes, they can mount an enhanced response.[18] This immunological principle—that a PCV-first sequence is superior to a PPSV23-first sequence—is not merely an academic observation; it forms the central scientific rationale that underpins the complex sequential vaccination schedules currently recommended by national advisory bodies like the ACIP. The entire "PCV-first" paradigm is a direct clinical application of these fundamental immunological differences, designed to maximize both the quality and durability of the immune response (from the PCV) and the breadth of serotype coverage (from PPSV23).[25]

Clinical Efficacy and Real-World Effectiveness

The clinical value of a vaccine is ultimately determined by its ability to prevent disease in target populations. For PPSV23, the evidence base reveals a clear and critical dichotomy: the vaccine is demonstrably effective against invasive disease but shows inconsistent and limited efficacy against non-invasive pneumonia.

Prevention of Invasive Pneumococcal Disease (IPD)

The evidence supporting the effectiveness of PPSV23 in preventing IPD (bacteremia and meningitis) is robust and has been consistently demonstrated across numerous studies.[1] In immunocompetent adults, observational studies and clinical trials have estimated the vaccine's effectiveness to be in the range of 50% to 85% against IPD caused by the 23 serotypes contained in the vaccine.[4]

A comprehensive systematic review and meta-analysis published in Pathogens in 2023, which informed recent ACIP recommendations, synthesized data from nine observational studies. This analysis calculated a pooled vaccine effectiveness for PPSV23 of [45%] (95% Confidence Interval [CI]: 37% to 51%) against vaccine-type IPD in adults.[28] This statistically significant finding confirms a substantial protective effect against the most severe forms of pneumococcal infection. The vaccine's real-world impact has also been demonstrated in high-risk populations. For instance, a study in Canadian patients with HIV reported that vaccination was associated with a dramatic decrease in the incidence of IPD, from 768 cases per 100,000 person-years to 244 per 100,000 person-years.[5]

The Controversy of Pneumonia Prevention

In stark contrast to the consistent data on IPD, the effectiveness of PPSV23 in preventing non-bacteremic pneumococcal pneumonia (NBPP) and all-cause community-acquired pneumonia (CAP) is a subject of considerable controversy and inconsistent evidence.[7] Multiple sources characterize its protective effect against pneumonia as "low" or "unreliable".[4] Some analyses suggest that any effectiveness it may have is declining over time [32], while others find the data inconclusive.[17]

The same 2023 meta-analysis that found significant protection against IPD also evaluated PPSV23's effectiveness against vaccine-type pneumococcal pneumonia, pooling data from five studies. The analysis yielded a pooled effectiveness of only [18%] (95% CI: -4% to 35%).[28] The confidence interval for this estimate crosses zero, indicating that the observed effect is not statistically significant. This lack of clear evidence has led some experts to conclude that referring to PPSV23 as the "pneumonia vaccine" is a misnomer that creates inaccurate patient expectations.[6]

This distinction between preventing IPD and NBPP is the most critical nuance in understanding the vaccine's clinical role. While IPD is less common than NBPP, its associated mortality is far higher.[4] Therefore, the primary public health value of PPSV23 lies not in reducing the overall incidence of pneumonia, but in preventing the deadliest complications of pneumococcal infection. This reframes the vaccine's utility, justifying its continued use as a targeted intervention against severe disease, often in combination with PCVs that have demonstrated efficacy against NBPP.

Effectiveness Across Key Patient Populations

The immune response to PPSV23 and its resulting clinical effectiveness can vary significantly across different patient populations.

• [The Elderly:] While older adults are a primary target group for vaccination, the phenomenon of immunosenescence—the age-associated decline in immune function—can attenuate the response to the vaccine.[7] Some evidence suggests that vaccine-conferred protection may be lower in adults aged 75 years and older compared to younger adults.[33]
• [Immunocompromised Individuals:] Patients with compromised immune systems, whether due to disease (e.g., HIV, malignancy, chronic renal failure) or immunosuppressive therapy, consistently show a reduced immune response and lower clinical effectiveness from PPSV23.[8] For example, a study using a test-negative design in patients with reduced kidney function found no clear evidence of PPSV23 effectiveness against hospitalization for S. pneumoniae or bacteremia.[34]
• [Patients with Chronic Conditions:] The evidence in patients with chronic medical conditions is mixed. While some high-risk populations may not respond as well, one real-world case-control study in elderly outpatients with chronic respiratory diseases found that PPSV23 vaccination was associated with a significant reduction in the odds of developing pneumococcal pneumonia (adjusted odds ratio of 0.39).[30]

Duration of Protection and Waning Immunity

The T-cell independent nature of the immune response to PPSV23 results in protection that wanes over time. In healthy adults, protective antibody levels are generally maintained for at least five years.[10] However, this decline can be more rapid in older adults and in individuals with underlying medical conditions.[10] Studies have shown that vaccine effectiveness is lower in individuals whose vaccination occurred more than five years prior to potential exposure.[33] This evidence of waning immunity provides the rationale for official recommendations for revaccination in specific high-risk groups to maintain protection.[12]

Indications and Official Recommendations (ACIP/CDC)

The recommendations for the use of PPSV23 are issued by national public health bodies, with the guidelines from the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) serving as the standard of care in the United States. These recommendations have evolved significantly over time, reflecting the introduction of new conjugate vaccines.

Current Age-Based and Risk-Based Recommendations

PPSV23 is licensed by the U.S. Food and Drug Administration (FDA) for use in persons aged 2 years and older who are at increased risk for pneumococcal disease, and for all adults aged 50 years and older.[5] However, current ACIP recommendations have refined its specific role.

As of an October 2024 update, ACIP recommends that all pneumococcal vaccine-naïve adults aged 50 years and older receive a pneumococcal conjugate vaccine (PCV).[36] In this context, PPSV23 is no longer recommended as a standalone, first-line option for this population. Instead, its primary role is as part of a two-dose sequential series: a single dose of 15-valent PCV (PCV15) followed by a dose of PPSV23.[36] This is presented as an alternative to receiving a single dose of a higher-valency conjugate vaccine (PCV20 or PCV21).

For adults aged 19 through 64 years, pneumococcal vaccination remains risk-based. Individuals with certain chronic medical conditions, immunocompromising conditions, or other risk factors are recommended for vaccination.[38] A comprehensive list of these conditions is provided in Table 1.

Table 1: High-Risk Conditions Warranting Pneumococcal Vaccination in Adults Aged 19–64

Category	Specific Conditions
Chronic Medical Conditions	Chronic heart disease (including congestive heart failure and cardiomyopathies)Chronic lung disease (including COPD, emphysema, and asthma)Chronic liver diseaseDiabetes mellitus 38
Immunocompromising Conditions	Congenital or acquired immunodeficiencyHIV infectionChronic renal failure or nephrotic syndromeGeneralized malignancyHodgkin disease, leukemia, lymphoma, multiple myelomaSolid organ transplantIatrogenic immunosuppression (e.g., long-term systemic corticosteroids, radiation therapy) 38
Functional or Anatomic Asplenia	Sickle cell disease and other hemoglobinopathiesCongenital or acquired asplenia 5
Other Specific Risk Factors	AlcoholismCigarette smokingCerebrospinal fluid (CSF) leakCochlear implant 38

Use in Special Populations

• [Children:] PPSV23 is explicitly [not] recommended or approved for use in children younger than 2 years of age. This is due to the immaturity of their immune systems, which are unable to mount an effective T-cell independent response to polysaccharide antigens.[1] For children aged 2 through 18 years with high-risk conditions (e.g., asplenia, sickle cell disease, immunocompromise), PPSV23 is recommended, but only as part of a series after the child has completed the routine childhood PCV immunization schedule.[5]
• [HIV Infection:] While early studies demonstrated a significant reduction in IPD among HIV-infected individuals who received PPSV23, concerns about the quality and durability of the immune response in this population have been noted.[5] The 2008 World Health Organization (WHO) guidelines, for example, did not recommend routine PPSV23 use in HIV patients due to low levels of evidence.[5] However, current ACIP recommendations do include HIV infection as an immunocompromising condition that warrants a sequential PCV and PPSV23 vaccination schedule.[42]

Administration, Dosage, and Vaccination Schedules

Proper administration and adherence to recommended schedules are paramount to maximizing the protective benefit of PPSV23. The current guidelines are complex, stratified by age, underlying risk, and prior pneumococcal vaccination history.

Standard Dosage and Routes of Administration

The standard dose of PPSV23 is a single 0.5 mL injection.[12] A unique feature of PPSV23 compared to PCVs is its flexibility in the route of administration; it can be given either intramuscularly (IM) or subcutaneously (Subcut).[12] The preferred injection sites are the deltoid muscle in the upper arm or the lateral mid-thigh.[12] Care must be taken to avoid intravascular or intradermal injection.[12]

The Role of PPSV23 in Sequential Vaccination Strategies with PCVs

The current standard of care, as defined by ACIP, integrates PPSV23 into sequential schedules with PCVs. The guiding principle for any pneumococcal vaccine-naïve adult is to initiate vaccination with a conjugate vaccine to establish a robust, T-cell dependent memory response. The two primary options are:

1. A single dose of a higher-valency PCV (PCV20 or PCV21), which completes the series.
2. A two-dose series of PCV15 followed by a dose of PPSV23.[36]

The intervals between doses in the sequential series are critical and vary by risk profile:

• [Standard Interval:] For most adults receiving the PCV15/PPSV23 series, the recommended interval between the PCV15 dose and the subsequent PPSV23 dose is at least 1 year.[26]
• [Shortened Interval for High-Risk Individuals:] For adults with certain high-risk conditions—specifically immunocompromising conditions, a cochlear implant, or a cerebrospinal fluid leak—a minimum interval of 8 weeks between PCV15 and PPSV23 can be considered. This allows for the broader serotype protection afforded by PPSV23 to be achieved more rapidly in those at highest risk of disease.[26]

If a patient has previously received PPSV23 but not a PCV, a dose of a PCV should be administered at least 1 year after the most recent PPSV23 dose.[26] The detailed, scenario-based recommendations are summarized in Table 2.

Table 2: ACIP Recommended Pneumococcal Vaccination Schedules for Adults Based on Age, Risk Profile, and Vaccination History (October 2024 Update)

Patient Population/Risk Group	Prior Pneumococcal Vaccines Received	Recommended Vaccination Schedule
Adults ≥50 years	None, or unknown history	Option A: 1 dose of PCV20 or PCV21. Option B: 1 dose of PCV15, followed by 1 dose of PPSV23 ≥1 year later.*
	PPSV23 only	1 dose of PCV15, PCV20, or PCV21 ≥1 year after last PPSV23 dose.
	PCV13 only	1 dose of PCV20 or PCV21 ≥1 year after PCV13 dose.
	PCV13 and PPSV23 (both before age 65)	1 dose of PCV20 or PCV21 ≥5 years after last pneumococcal vaccine dose.
Adults 19–49 years with Immunocompromise, CSF Leak, or Cochlear Implant	None, or unknown history	Option A: 1 dose of PCV20 or PCV21. Option B: 1 dose of PCV15, followed by 1 dose of PPSV23 ≥8 weeks later.
	PPSV23 only	1 dose of PCV15, PCV20, or PCV21 ≥1 year after last PPSV23 dose.
	PCV13 only	1 dose of PCV20 or PCV21 ≥1 year after PCV13 dose.
	PCV13 and 1 dose of PPSV23	1 dose of PCV20 or PCV21 ≥5 years after last pneumococcal vaccine dose.
Adults 19–49 years with other Chronic Conditions (Table 1)	None, or unknown history	Option A: 1 dose of PCV20 or PCV21. Option B: 1 dose of PCV15, followed by 1 dose of PPSV23 ≥1 year later.
	PPSV23 only	1 dose of PCV15, PCV20, or PCV21 ≥1 year after last PPSV23 dose.
	PCV13 only	1 dose of PCV20 or PCV21 ≥1 year after PCV13 dose.
	PCV13 and 1 dose of PPSV23	No further doses recommended. Re-evaluate at age 50.

Adapted from ACIP recommendations.[36]

*A minimum interval of 8 weeks between PCV15 and PPSV23 can be considered for adults ≥50 years with an immunocompromising condition, cochlear implant, or CSF leak.

Revaccination Guidelines for High-Risk Groups

Routine revaccination with PPSV23 is not recommended for immunocompetent individuals.[12] However, for individuals at the highest risk of serious pneumococcal disease and rapid waning of antibodies, a second dose of PPSV23 is indicated. This applies to persons aged 19-64 with immunocompromising conditions or functional/anatomic asplenia. For these individuals, a second PPSV23 dose should be administered 5 years after the first PPSV23 dose.[35] A third dose is generally not recommended.

Safety, Tolerability, and Risk Management

PPSV23 has a well-established safety profile based on decades of post-market surveillance and data from numerous clinical trials. It is generally considered a very safe and well-tolerated vaccine.[48]

Adverse Event Profile

The vast majority of adverse events following PPSV23 administration are mild, localized to the injection site, and resolve within a few days without intervention.[49]

• [Common Reactions:] Data from large clinical trials provide precise frequencies for the most common adverse reactions reported after a first dose of PPSV23. These include:
• Injection-site pain, soreness, or tenderness (60.0%) [5]
• Injection-site swelling or induration (hardening) (20.3%) [5]
• Headache (17.6%) [5]
• Injection-site erythema (redness) (16.4%) [8]
• Asthenia (weakness) and fatigue (13.2%) [8]
• Myalgia (muscle pain) (11.9%) [8]
• [Less Common Reactions:] Systemic reactions such as low-grade fever are reported in less than 5% of recipients.[8] Chills and muscle aches can also occur.[2]
• [Reactions Following Revaccination:] A notable characteristic of PPSV23 is that local adverse reactions are significantly more common and more intense following a second (booster) dose compared to the initial dose.[8] For example, one study noted the local adverse reaction rate was 79.3% after revaccination versus 52.9% after initial vaccination.[48] This increased reactogenicity upon revaccination may stem from high levels of pre-existing antibodies forming immune complexes at the injection site. This phenomenon can be a source of vaccine hesitancy for patients requiring a second dose, underscoring the importance of proactive patient counseling to manage expectations and ensure adherence to schedules for the highest-risk individuals.
• [Severe Reactions:] Severe allergic reactions, such as anaphylaxis, are very rare but can be life-threatening.[3] As with all injectable vaccines, administration should occur in a setting where personnel and equipment are available to manage an acute anaphylactic reaction.

Contraindications, Warnings, and Precautions

While the vaccine is safe for most eligible individuals, certain conditions warrant caution or contraindicate its use.

• [Absolute Contraindication:] The only absolute contraindication to receiving PPSV23 is a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of the vaccine or to any of its components.[8]
• [Warnings and Precautions:]
• [Acute Illness:] Vaccination should be deferred for individuals with a moderate or severe acute illness, with or without fever. It can be administered once the acute phase of the illness has resolved.[2] Vaccination is permissible for those with minor illnesses, such as a common cold.[2]
• [Cardiopulmonary Function:] Caution should be exercised when administering the vaccine to individuals with severely compromised cardiovascular or pulmonary function, for whom a systemic reaction could pose a significant risk.[8]
• [Altered Immunocompetence:] Patients with conditions or on therapies that suppress the immune system may have a diminished antibody response to the vaccine.[8] While the vaccine is still recommended for these high-risk groups, the level of protection achieved may be suboptimal.

Management of Clinically Significant Drug Interactions

The potential for a diminished vaccine response is the primary concern regarding drug interactions.

• [Immunosuppressive Therapy:] Patients receiving immunosuppressive treatments—including cancer chemotherapy, radiation therapy, high-dose corticosteroids, anti-rejection medications (e.g., cyclosporine), and certain biologic agents (e.g., belimumab, certolizumab pegol)—may have a significantly reduced immune response to PPSV23.[42] To mitigate this, vaccination should, whenever feasible, be completed at least two weeks prior to the initiation of immunosuppressive therapy.[35] If vaccination occurs during immunosuppressive therapy, revaccination may be necessary at least three months after therapy is discontinued, once immune competence is restored.[42]
• [Zoster Vaccine:] Co-administration of PPSV23 with the older, live-attenuated zoster vaccine (Zostavax) was found to reduce the immune response to the zoster vaccine. It was recommended that the two vaccines be administered at least four weeks apart.[42] This interaction is not a significant concern with the currently recommended recombinant zoster vaccine (Shingrix).
• [Coadministration with Other Vaccines:] PPSV23 can be safely and effectively co-administered with most other routine adult vaccines, including the seasonal influenza vaccine. When given at the same visit, they should be administered using separate syringes and at different anatomical sites.[6]

Conclusion: The Evolving Role of PPSV23 in the Era of Higher-Valency Conjugate Vaccines

The 23-valent pneumococcal polysaccharide vaccine has been a mainstay of adult pneumococcal disease prevention for four decades. Its legacy is built on a foundation of proven effectiveness against the most severe and life-threatening forms of the disease. The primary and enduring strength of PPSV23 is its broad serotype coverage, which remains wider than any single pneumococcal conjugate vaccine currently licensed.[5] This breadth is critical for protecting against the diverse range of serotypes that cause invasive disease in adults.

However, the vaccine's utility is defined as much by its limitations as by its strengths. Its T-cell independent mechanism of action results in an immune response that lacks robust, long-term memory, is ineffective in the youngest children, and provides inconsistent and clinically insignificant protection against non-bacteremic pneumococcal pneumonia.[10]

The introduction and continued development of higher-valency PCVs (PCV15, PCV20, and PCV21) for adults has fundamentally reshaped the landscape of pneumococcal prevention.[9] These technologically advanced vaccines overcome the key immunological shortcomings of PPSV23 by inducing a durable, T-cell dependent memory response. Consequently, PPSV23 is no longer positioned as the primary, standalone vaccine for most adult populations in the United States.

Instead, its role has transitioned to that of an essential partner in a sophisticated, sequential vaccination strategy. The ACIP-recommended option of administering PCV15 followed by PPSV23 is a direct clinical application of immunological principles, designed to achieve the best of both worlds: the superior immunogenicity and memory of a conjugate vaccine and the expanded serotype coverage of the polysaccharide vaccine. This complex strategy reflects a nuanced public health approach to optimize protection by leveraging the distinct advantages of two different vaccine technologies. As research continues and even higher-valency conjugate vaccines are developed, it is possible that they may one day provide sufficient breadth of coverage to render the sequential approach, and thus PPSV23, obsolete. For the present, however, PPSV23 remains a vital and irreplaceable component in the comprehensive strategy to reduce the burden of severe pneumococcal disease in adults.

Works cited

1. Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5893217/
2. Pneumococcal polysaccharide vaccine - what you need to know Information - Mount Sinai, accessed August 25, 2025, https://www.mountsinai.org/health-library/special-topic/pneumococcal-polysaccharide-vaccine-what-you-need-to-know
3. Pneumococcal polysaccharide vaccine (PPSV23) - what you need to know, accessed August 25, 2025, https://sbrmc.adam.com/content.aspx?productid=117&pid=1&gid=007607
4. Pneumococcal Vaccines (PPSV23 and PCV13) - Vermont Department of Health, accessed August 25, 2025, https://healthvermont.gov/sites/default/files/documents/2016/11/ID_PneumoVaccine.pdf
5. Pneumococcal polysaccharide vaccine - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Pneumococcal_polysaccharide_vaccine
6. Pneumococcal Vaccination: Optimizing Preventive Strategies and Reducing Disease Burden - U.S. Pharmacist, accessed August 25, 2025, https://www.uspharmacist.com/article/pneumococcal-vaccination-optimizing-preventive-strategies-and-reducing-disease-burden
7. PNEUMOCOCCAL VACCINE EFFICACY AND REAL-WORLD EVIDENCE - College of Family Physicians Singapore, accessed August 25, 2025, https://cfps.org.sg/publications/the-singapore-family-physician/article/1975_pdf
8. Package Insert - PNEUMOVAX 23 - FDA, accessed August 25, 2025, https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-PNEUMOVAX-23_0.pdf
9. Pneumococcal Vaccine - StatPearls - NCBI Bookshelf, accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507794/
10. About Pneumococcal Vaccines: For Providers - CDC, accessed August 25, 2025, https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html
11. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4635730/
12. pneumovax_pi.pdf - Merck.com, accessed August 25, 2025, https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf
13. Conjugate Vaccine vs Polysaccharide Vaccine - Creative Diagnostics, accessed August 25, 2025, https://www.creative-diagnostics.com/conjugate-vaccine-vs-polysaccharide-vaccine.htm
14. Conjugate vaccines and polysaccharide response - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1405863/
15. Pneumovax 23 (pneumococcal 23-valent polysaccharide) - WebMD, accessed August 25, 2025, https://www.webmd.com/drugs/2/drug-5546/pneumovax-23-injection/details
16. Pneumococcal vaccine polyvalent (intramuscular route, subcutaneous route) - Side effects & uses - Mayo Clinic, accessed August 25, 2025, https://www.mayoclinic.org/drugs-supplements/pneumococcal-vaccine-polyvalent-intramuscular-route-subcutaneous-route/description/drg-20065538
17. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Preventing Community-Acquired Pneumonia in Adults: A Population-Based Cohort Study - MDPI, accessed August 25, 2025, https://www.mdpi.com/2076-393X/12/9/1023
18. Pneumococcal immune responses 1 mo after PcV13 and PPsV23 (evaluable immunogenicity population) - ResearchGate, accessed August 25, 2025, https://www.researchgate.net/figure/Pneumococcal-immune-responses-1-mo-after-PcV13-and-PPsV23-evaluable-immunogenicity_tbl2_260430264
19. pubmed.ncbi.nlm.nih.gov, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/18378430/#:~:text=Conjugation%20of%20capsular%20polysaccharides%20with,the%20same%20time%20reducing%20vaccine
20. Pneumococcal Vaccination of Adults: Polysaccharide or Conjugate? - The Medical Letter, accessed August 25, 2025, https://secure.medicalletter.org/TML-article-1314d
21. Conjugate vaccine - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Conjugate_vaccine
22. On the mechanisms of conjugate vaccines - PNAS, accessed August 25, 2025, https://www.pnas.org/doi/10.1073/pnas.1819612116
23. Conjugate Vaccine Mechanisms, Design, and Immunological Memory | The Scientist, accessed August 25, 2025, https://www.the-scientist.com/conjugate-vaccine-mechanisms-design-and-immunological-memory-73184
24. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease - HealthPartners, accessed August 25, 2025, https://www.healthpartners.com/knowledgeexchange/display/document-rn19747
25. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5779453/
26. Administering Pneumococcal Vaccine: For Providers - CDC, accessed August 25, 2025, https://www.cdc.gov/vaccines/vpd/pneumo/hcp/administering-vaccine.html
27. Pneumococcus Vaccine - AAFP, accessed August 25, 2025, https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/pneumococcus-vaccine.html
28. Systematic Review and Meta-Analysis of the Efficacy and ... - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/37242402/
29. (PDF) Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults - ResearchGate, accessed August 25, 2025, https://www.researchgate.net/publication/364249555_Systematic_Review_and_Meta-Analysis_of_the_Efficacy_and_Effectiveness_of_Pneumococcal_Vaccines_in_Adults
30. Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8051051/
31. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study - Oxford Academic, accessed August 25, 2025, https://academic.oup.com/cid/article/60/10/1472/338296
32. Full article: Strategies for pneumococcal vaccination in older adults in the coming era, accessed August 25, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2328963
33. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/33478306/
34. Pneumococcal vaccination effectiveness (PCV13 and PPSV23) in individuals with and without reduced kidney function: a test-negative design study - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11194481/
35. Pneumococcal Vaccine - Infectious Diseases - Merck Manual Professional Edition, accessed August 25, 2025, https://www.merckmanuals.com/professional/infectious-diseases/immunization/pneumococcal-vaccine
36. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR - CDC, accessed August 25, 2025, https://www.cdc.gov/mmwr/volumes/74/wr/mm7401a1.htm
37. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024 - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/39773952/
38. Pneumococcal Vaccine for Adults Aged ≥19 Years ... - CDC, accessed August 25, 2025, https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm
39. Pneumococcal Vaccine Recommendations | Pneumococcal | CDC, accessed August 25, 2025, https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
40. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR - CDC, accessed August 25, 2025, https://www.cdc.gov/mmwr/volumes/73/wr/mm7336a3.htm
41. ACIP Recommendations | PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine), accessed August 25, 2025, https://prevnar20adult.pfizerpro.com/cdc-recommendations
42. Pneumovax 23 (pneumococcal vaccine polyvalent) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 25, 2025, https://reference.medscape.com/drug/pneumovax-23-pneumococcal-vaccine-polyvalent-343164
43. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - CDC, accessed August 25, 2025, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
44. Chapter 17: Pneumococcal Disease | Pink Book - CDC, accessed August 25, 2025, https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
45. Standing Orders for Administering Pneumococcal ... - Immunize.org, accessed August 25, 2025, https://www.immunize.org/wp-content/uploads/catg.d/p3075.pdf
46. Ask The Experts About Vaccines: Pneumococcal | Recommendations for Adults, accessed August 25, 2025, https://www.immunize.org/ask-experts/topic/pneumococcal/recommendations-adults/
47. Pneumococcal Vaccine Timing for Adults - Vermont Department of Health, accessed August 25, 2025, https://www.healthvermont.gov/sites/default/files/documents/2016/11/ID_PneumoVaccineHCP.pdf
48. information sheet - pneumococcal vaccine - World Health Organization (WHO), accessed August 25, 2025, https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/pneumococcal-vaccine-rates-information-sheet.pdf
49. Pneumococcal Vaccine Safety - CDC, accessed August 25, 2025, https://www.cdc.gov/vaccine-safety/vaccines/pneumococcal.html
50. Pneumococcal disease - The Australian Immunisation Handbook, accessed August 25, 2025, https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/pneumococcal-disease
51. PNEUMOVAX® 23 | Merck Canada, accessed August 25, 2025, https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/PNEUMOVAX_23-CI_E.pdf
52. Pneumococcal vaccine - NHS, accessed August 25, 2025, https://www.nhs.uk/vaccinations/pneumococcal-vaccine/
53. PPSV23 Vaccine VIS - CDC, accessed August 25, 2025, https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-polysaccharide.html
54. Pneumovax 23: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 25, 2025, https://www.drugs.com/pneumovax-23.html
55. Pneumococcal Vaccine (Pneumovax 23): Benefits - Cleveland Clinic, accessed August 25, 2025, https://my.clevelandclinic.org/health/drugs/18520-pneumococcal-vaccine-polyvalent-solution-for-injection
56. Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Open Forum Infectious Diseases | Oxford Academic, accessed August 25, 2025, https://academic.oup.com/ofid/article/12/2/ofaf069/8002225